Key points are not available for this paper at this time.
This study presents a hybrid hydrogel system designed for the targeted delivery of letrozole, a key therapeutic agent in breast cancer treatment. Letrozole-loaded poly(lactic-co-glycolic acid) (PLGA) microparticles were embedded within a poly(2-hydroxyethyl methacrylate) (pHEMA) matrix coated onto acrylamide-grafted low-density polyethylene (AAm-g-LDPE), yielding a mechanically stable system with tunable drug release. Field emission scanning electron microscopy (FE-SEM) and confocal microscopy confirmed uniform microparticle distribution. In vitro release studies in simulated uterine fluid (SUF) at 37 °C demonstrated a sustained release profile over 32 days, with a reduced initial burst effect (~15% lower than conventional PLGA systems). The system’s release kinetics followed the Higuchi model (R2 = 0.803–0.996), indicating Fickian diffusion. This hybrid hydrogel offers enhanced drug stability, reduced dosing frequency, and potential for personalized hormone therapy, improving patient compliance, particularly for individuals with physical or cognitive impairments.
Mohsin et al. (Tue,) studied this question.